Skip to main content
Year archive

NOXOPHARM LIMITED — 2018 filings

All 83 regulatory filings released by NOXOPHARM LIMITED (NOX) in 2018, sourced directly from the official regulator.

83 Filings
2018 Period
2018 filings (83)
Filing Released Lang
Appendix 3B 12 pages 496.4KB
Capital/Financing Update
2018-12-20 English
Section 708 Certificate 1 page 235.4KB
Regulatory Filings
2018-12-20 English
Change of Director's Interest Notice - GK 4 pages 226.8KB
Director's Dealing
2018-12-20 English
NOX Receives $3.26M Federal Govt R&D Rebate 2 pages 164.8KB
Capital/Financing Update
2018-12-19 English
DARRT-1 study advancing on basis of positive clinical data 3 pages 170.1KB
Regulatory Filings
2018-12-10 English
NOX announces Positive Data from CEP-1 Study of Veyonda 4 pages 206.6KB
Regulatory Filings
2018-11-28 English
NOX 2018 AGM Presentations 80 pages 13.9MB
Regulatory Filings
2018-11-20 English
Appointment of Mr John Moore as Non-Executive Director 2 pages 253.1KB
Board/Management Information
2018-11-20 English
Results of Meeting 2 pages 154.7KB
Declaration of Voting Results & Voting Rights Announcements
2018-11-20 English
Initial Director's Interest Notice 2 pages 184.2KB
Director's Dealing
2018-11-20 English
NOX 2018 AGM Information 2 pages 156.2KB
AGM Information
2018-11-19 English
NOX to Present Clinical Data at COSA Annual Meeting 6 pages 1.7MB
Investor Presentation
2018-11-12 English
Corporate Presentation 38 pages 8.2MB
Investor Presentation
2018-11-07 English
Appendix 4C - quarterly 10 pages 383.2KB
Interim / Quarterly Report
2018-10-25 English
NOX makes key executive appointment 3 pages 166.6KB
Board/Management Information
2018-10-21 English
Notice of Annual General Meeting & Proxy Form 22 pages 823.7KB
AGM Information
2018-10-04 English
Noxopharm Releases Report on Key Progress of Subsidiary 11 pages 345.7KB
Management Reports
2018-10-03 English
Appendix 3B 11 pages 487.3KB
Capital/Financing Update
2018-10-01 English
Section 708 Certificate 1 page 236.5KB
Capital/Financing Update
2018-10-01 English
Appendix 3B 13 pages 485.7KB
Share Issue/Capital Change
2018-09-27 English
Section 708 Certificate 1 page 244.2KB
Capital/Financing Update
2018-09-27 English
Change of Director's Interest Notice - PM 3 pages 164.9KB
Director's Dealing
2018-09-27 English
Corporate Governance Statement - 2018 15 pages 479.7KB
Governance Information
2018-09-26 English
Corporate Governance Statement - Appendix 4G 12 pages 248.1KB
Governance Information
2018-09-26 English
Annual Report to shareholders 72 pages 2.0MB
Annual Report
2018-09-26 English
NOX Subsidiary Announces Important Drug Discovery 3 pages 219.2KB
Regulatory Filings
2018-09-23 English
NOX to support expanded LuPIN study 2 pages 186.6KB
Regulatory Filings
2018-09-04 English
Appendix 4E and Audited Financial Statements 54 pages 1.5MB
Annual Report
2018-08-29 English
Nyrada-Key progress with cholesterol-lowering drug candidate 3 pages 172.4KB
Capital/Financing Update
2018-08-26 English
VEYONDA - Registered Trade Mark for NOX66 2 pages 152.7KB
Regulatory Filings
2018-08-19 English
NOX Corporate Presentation FNN-Shaw&Partners Investor Event 22 pages 1.0MB
Investor Presentation
2018-08-13 English
Appendix 3B 13 pages 540.0KB
Capital/Financing Update
2018-08-08 English
Change of Director's Interest Notice - ID 3 pages 224.6KB
Director's Dealing
2018-08-08 English
Change of Director's Interest Notice - PM 3 pages 224.6KB
Director's Dealing
2018-08-08 English
Change of Director's Interest Notice - GK 3 pages 226.9KB
Director's Dealing
2018-08-08 English
Interim NOX66 Radiotherapy Clinical Data 3 pages 264.2KB
Investor Presentation
2018-08-07 English
Appendix 4C - quarterly 10 pages 552.8KB
Interim / Quarterly Report
2018-07-29 English
Securities to be released from Escrow 1 page 76.6KB
Share Issue/Capital Change
2018-07-09 English
Release of DARRT-1 Preliminary Safety Data 2 pages 241.7KB
Regulatory Filings
2018-07-08 English
Pre-Clinical data confirms Radio-Enhancing potential 3 pages 168.0KB
Regulatory Filings
2018-07-04 English
Noxopharm Corporate Presentation for Public Briefing 21 pages 13.8MB
Investor Presentation
2018-06-06 English
Noxopharm releases Nyrada Corporate Presentation 25 pages 1.6MB
Investor Presentation
2018-06-06 English
End-of-Study Clinical Data shows benefit of NOX66 3 pages 270.8KB
Regulatory Filings
2018-06-04 English
Noxopharm 2018 Mid-Year Investor Briefings 2 pages 152.2KB
Investor Presentation
2018-05-30 English
Appendix 3B 12 pages 538.1KB
Capital/Financing Update
2018-05-27 English
Section 708 Certificate 1 page 236.9KB
Share Issue/Capital Change
2018-05-27 English
NOX to present at American Society of Clinical Oncology 3 pages 259.9KB
Investor Presentation
2018-05-21 English
Appendix 3B 12 pages 388.9KB
Capital/Financing Update
2018-05-20 English
Section 708 Certificate 1 page 235.4KB
Share Issue/Capital Change
2018-05-20 English
Securities to be released from Voluntary Escrow 1 p
Capital/Financing Update
2018-05-20 English
Change in substantial holding 3 pages 159.5KB
Major Shareholding Notification
2018-05-20 English
KZA: Progress Report 1 page 149.1KB
Capital/Financing Update
2018-05-20 English
Noxopharm 2018 Mid-Year Investor Briefings 2 pages 151.2KB
Investor Presentation
2018-05-17 English
Results of Meeting 2 pages 141.7KB
Declaration of Voting Results & Voting Rights Announcements
2018-05-14 English
NOX CEO interview updates the company's current R&D program 2 pages 158.5KB
Investor Presentation
2018-05-06 English
NOX CEO interview on near complete NOX66 chemotherapy trial 2 pages 159.2KB
Regulatory Filings
2018-05-02 English
Appendix 4C - quarterly 9 pages 540.6KB
Interim / Quarterly Report
2018-04-26 English
NOX CEO interview on Radiotherapy Clinical Programs 2 pages 160.3KB
Investor Presentation
2018-04-26 English
St Vincent's Hospital study passes first milestone 3 pages 172.5KB
Regulatory Filings
2018-04-16 English
Notice of Extraordinary General Meeting / Proxy Form 13 pages 1.2MB
Proxy Solicitation & Information Statement
2018-04-08 English
Change in substantial holding 3 pages 213.7KB
Major Shareholding Notification
2018-04-05 English
Change in substantial holding 2 pages 163.9KB
Regulatory Filings
2018-04-05 English
NOX Mid-Year Briefings 2 pages 235.6KB
Investor Presentation
2018-04-04 English
DARRT-1 Clinical Study commences 2 pages 185.6KB
Regulatory Filings
2018-04-04 English
Appendix 3B 12 pages 535.9KB
Capital/Financing Update
2018-03-28 English
Section 708 Certificate 1 page 236.9KB
Capital/Financing Update
2018-03-28 English
NOX raises $10.8 M to advance clinical program 2 pages 157.1KB
Capital/Financing Update
2018-03-22 English
Evidence of Abscopal Responses in Patients 3 pages 262.1KB
Investor Presentation
2018-03-20 English
Trading Halt 2 pages 458.5KB
Regulatory Filings
2018-03-20 English
Corporate Presentation - Post Interim Clinical Data Release 27 pages 11.6MB
Investor Presentation
2018-03-11 English
FNN Interview with Noxopharm CEO 2 pages 170.1KB
Regulatory Filings
2018-03-08 English
NOX Reports NOX66 Clinical Data 4 pages 484.1KB
Regulatory Filings
2018-03-05 English
Trading Halt 2 pages 460.4KB
Regulatory Filings
2018-03-04 English
Appendix 4D and Half Year Accounts 20 pages 3.5MB
Regulatory Filings
2018-02-22 English
Update accompanying Half Year Report 2 pages 255.9KB
Interim / Quarterly Report
2018-02-22 English
NOX closes $4m capital raising for US subsidiary Nyrada Inc 3 pages 481.7KB
Capital/Financing Update
2018-02-15 English
Appendix 4C - quarterly 9 pages 466.2KB
Interim / Quarterly Report
2018-01-30 English
Appendix 3B 12 pages 538.4KB
Capital/Financing Update
2018-01-24 English
Section 708 Certificate 1 page 237.3KB
Share Issue/Capital Change
2018-01-24 English
KZA: Receipt of securities in Noxopharm Limited (NOX) 1
Capital/Financing Update
2018-01-21 English
Appendix 3B 12 pages 538.5KB
Share Issue/Capital Change
2018-01-17 English
Section 708 Certificate 1 page 236.5KB
Capital/Financing Update
2018-01-17 English
NOX receives FY17 R&D Tax Rebate 3 pages 336.9KB
Capital/Financing Update
2018-01-16 English